Peroxisome proliferation in the liver is a well-documented response that occurs in some species upon treatment with hypolipidemic drugs, such as fibrates. Typically, liver peroxisome proliferation has been estimated by direct counting via electron microscopy, as well as by gene expression, enzyme activity, and immunolabeling. We have developed a novel method for the immunofluorescent labeling of peroxisomes, using an antibody to the 70-kDa peroxisomal membrane protein (PMP70) coupled with fluorescent nanocrystals, Quantum Dots TM . This method is applicable to standard formalin-fixed, paraffin-embedded tissues. Using this technique, a dose-dependent increase in PMP70 labeling was evident in formalin-fixed liver sections from fenofibrate-treated rats. In formalin-fixed liver sections from cynomolgus monkeys given ciprofibrate, quantitative image analysis showed a statistically significant increase in PMP70 labeling compared to control; the increase in hepatic PMP70 protein levels was corroborated by immunoblotting using total liver protein. An increase in hepatic peroxisome number in ciprofibrate-treated monkeys was confirmed by electron microscopy. An advantage of the Quantum Dot/PMP70 method is that a single common protocol can be used to label peroxisomes from several different species, and many of the common problems that arise with immunolabeling, such as fading and low signal strength, are eliminated.
Peroxisomes are membrane-bound organelles that perform a variety of metabolic functions relating to lipid metabolism and energy balance. Peroxisomes are particularly abundant in cells from organs with high metabolic activity, such as the liver. The organelles appear roughly spherical in transmission electron micrographs and range between 0.1 mm and 1.0 mm in size (Titorenko and Rachubinski 2001) .
Peroxisomes perform critical functions in virtually every eukaryote. In mammals, these microbodies are thought to play a vital role in the biosynthesis of cholesterol, bile acids, ether phospholipids, and degradation of amino acids, purines, and prostaglandins (Titorenko and Rachubinski 2001) . However, the majority of the enzymatic processes that occur in peroxisomes are related to the b-oxidation of long-chain and branched-chain fatty acids (Beaufay et al., 1964) .
An increase in peroxisomes can be stimulated by exposure to a large class of structurally diverse industrial and pharmaceutical compounds termed ''peroxisome proliferators.'' Hypolipidemic drugs of the fibrate class, which includes ciprofibrate and fenofibrate, are well-known peroxisome proliferators (Corton et al., 2000; Klaunig et al., 2003) . The mechanism by which the fibrates cause an increase in peroxisome number begins with their binding to peroxisome proliferator-activated receptor-alpha (PPAR-a). PPAR-a, one of three PPAR isotypes, which include PPAR-a, PPAR-b/D, and PPAR-g (Corton et al., 2000; Escher and Wahli, 2000) . PPAR-a, a ligand-dependent transcription factor, regulates gene expression by binding to peroxisome proliferatorresponse elements in enhancer sites of genes encoding proteins involved in the uptake, activation, and b-oxidation of fatty acids. Interestingly, the activation of PPAR-a results in the increased transcription of the genes encoding these peroxisomal enzymes in some species, but not others. In species sensitive to PPAR-a ligands, particularly the mouse and the rat, the induction of PPAR-a also leads to a dramatic increase in the number of hepatocellular peroxisomes, an increase in hepatocellular DNA synthesis (Peters et al., 1997) , and eventually, results in hepatocarcinogenesis (Gonzalez, 2002) .
The variation of responses among species to peroxisome proliferators has been extensively studied (Choudhury et al., 2000; Lawrence et al., 2001) and reviewed (Klaunig et al., 2003) . It is generally accepted that the mouse and rat are highly susceptible to peroxisome proliferation, while humans exhibit little or no increase in peroxisome number, increased peroxisomal enzyme expression, increased DNA synthesis, or hepatomegaly. There is, however, conflicting data concerning the incidence of peroxisome proliferation in nonhuman primates. Reddy et al. reported an increase in peroxisomal enzyme activities in rhesus and cynomolgus monkeys treated with the hypolipidemic drug, ciprofibrate, while other investigators found little or no increase in peroxisome number or size in the primate, using either hepatocytes in vitro or in whole animals (Blaauboer et al., 1990; Foxworthy et al., 1990; Graham et al., 1994; Makowska et al., 1992; Reddy et al., 1984) .
Many techniques have been used to study peroxisome proliferation, both in vivo and in vitro. These methods include expression analysis of genes encoding peroxisomal proteins (Hsu et al., 2001; Lawrence et al., 2001; Schrader et al., 1998) and direct measurements of enzyme activity (Blaauboer et al., 1990) . While these techniques are useful for obtaining information about relative increases in peroxisomal activity in different species and tissues, extrapolation of these data to the quantitation of peroxisome number is difficult.
Immunolabeling techniques have been used on fixed cells and tissue as well as purified protein extracts (Ackers et al., 2000; Dansen et al., 2000; Fahimi and Baumgart, 1999) . The use of these methods for quantitative analysis relies not only on the specificity of the antibodies and the suitability of the fluorophore conjugate, but is also dependent on the method of visualization and image analysis. Additionally, the specific tissues and species being analyzed and the method of fixation can lead to difficulty in the staining procedure. The current standard for the visualization and quantitation of peroxisomes is by electron microscopy coupled with either 3,3 0 -diaminobenzidine or cerium staining (Fahimi and Baumgart, 1999) . These methods are extremely useful for accurate peroxisomal imaging, but are very timeconsuming, costly, and labor-intensive.
We have developed a method for immunofluorescent staining of peroxisomes using a polyclonal antibody to the 70-kDa peroxisomal membrane protein (PMP70, also known as ABCD3 and PXMP1) and fluorescent cadmium selenide-based nanocrystals called Quantum Dots TM (Qdots). The unique composition and structure of these nanocrystals led to highly desirable optical properties, such as quantum yields of over 50%, narrowemission peaks, remarkable photostability, and a large Stokes shift, provided by an exceptionally broad excitation range. Using streptavidin-coated Quantum Dots and the PMP70 antibody, we successfully stained, visualized, and quantitated peroxisomes in standard formalin-fixed, paraffin-embedded rat and monkey liver sections after in vivo treatment with fibrates. We also detected peroxisomes in formalin-fixed slides prepared from a normal human liver.
MATERIALS AND METHODS
Fibrate treatment. Male cynomolgus monkeys (Macaca fascicularis) were treated for 15 days with 0, 3, 30, 150, or 400 mg/kg/day of ciprofibrate by oral gavage, as described (Hoivik et al., 2004) . Male Wistar rats were treated BID, 6 h between doses, with 0, 10, 20, or 200 mg/kg/day of fenofibrate by oral gavage for 10 days. Animals were sacrificed the day after the final dose.
Tissue preparation for immunohistochemistry. Livers were preserved in 10% neutral-buffered formalin and embedded in paraffin. Five-mm sections of the tissues were cut and mounted on slides, deparaffinized in xylene, and rehydrated in alcohol. Five-mm sections of formalin-fixed normal human liver on slides were purchased from Biogenix (San Ramon, CA).
Immunohistochemistry. The endogenous biotin sites were blocked using an Avidin/Biotin blocking kit (Vector Labs, Burlingame, CA) according to manufacturer's instructions. Goat antigens were blocked with 10% normal goat serum (NGS). The samples were incubated with rabbit anti-PMP70 (Affinity Bioreagents, Golden, CO), diluted 1:500 in 10% NGS followed by incubation in biotinylated goat anti-rabbit IgG (Sigma, St. Louis, MO), diluted 1:1000 in PBS and 605 nm streptavidin-coated Quantum Dots TM (Quantum Dot Corp., Hayward, CA) . The tissues were cover-slipped and counterstained using mounting media with DAPI (Vector Labs, Burlingame, CA).
Negative controls were prepared by eliminating the primary antibody from the staining protocol. Additional controls to test for primary antibody specificity were performed by incubating the PMP70 antibody with the 16-mer PMP70 immunogen (Affinity Bioreagents) and substituting this mixture for the primary antibody solution.
Fields for microscopic evaluation and subsequent image analysis were selected randomly. Slides were examined using an Olympus IX81 inverted microscope with a 100-watt mercury lamp. A DAPI filter set with a 360 6 20 nm excitation filter, a 460 6 25-nm emission filter, and a 400-nm beam splitter were used to view the DAPI nucleus stain. A filter set, containing a 480 6 20-nm excitation filter with a 505-nm beam splitter, and a 535-nm long pass emission filter were used to visualize the red 605-nm Quantum Dots while allowing the autofluorescence to remain green. All filters were obtained from Chroma Technology Corp., Rockingham, VT.
Image analysis. Microscopy was performed using 60X or 100X oil-immersion objectives on an Olympus IX81 inverted-fluorescent microscope. Images from the liver of ciprofibrate-treated primates were captured using a Photometrics TM CoolSnap HQ-12 bit, 20-MHz digital camera (Roper Scientific, Trenton, NJ). Images derived using separate filter sets for the red, blue, and green channels were overlaid using Slidebook 4.0.0.6 (Intelligent Imaging Innovations, Inc. Denver, CO). The filter set for the red channel contained a 535 6 25-nm excitation and a 610 6 3-nm emission filter with a 565-nm beam splitter. The green channel was visualized using 480 6 20-nm excitation and 535 6 25-nm emission filters with a 505-nm beam splitter. The filter set for the blue channel contained a 360 6 20-nm excitation filter, a 460 6 25-nm emission filter, and a 400-nm beam splitter. Images were exported as 8-bit TIF images before and after deconvolution, using Slidebook 4.0.0.6. Deconvolution was performed using the manufacturer's default values, which are: (i) no neighbors, (ii) maximum iterations, 20, (iii) subtraction constant: 0.9, (iv) theoretical spacing: 0.5, and (v) X Y edge padding of 25 25. Eight-bit TIF images were imported into Image-Pro Plus version 4.5 (Media Cybernetics, Silver Spring, MD) for analysis. The area in the red channel from bins 125-255 was determined for all images using a 3 3 3 pixel sampler.
Electron microscopy (EM) and biochemical analysis. The electron microscopy and biochemical analysis of the primate liver data presented in this paper are from Hoivik et al., 2004 ; the same primate samples from animals treated with ciprofibrate were examined using Quantum Dots.
Briefly, for EM, the periportal regions were selected for thin sectioning and stained with 5% methanolic uranyl acetate and Reynold's lead citrate. Five representative ultrastructural photomicrographs were taken per monkey in each group. There were four animals per dose-group and EM was performed for all animals in all dose groups. Parameters examined by EM were peroxisome number, volume, and size.
The activity of the following enzymes was determined for each primate liver sample: Carnitine acetyltransferase, catalase, enoyl-CoA hydratase, and palmitoyl-CoA oxidase. Methods are given in Hoivik et al., 2004. Sample preparation for immunoblotting. The protein fractions from individual snap-frozen livers of control, and ciprofibrate-treated cynomolgus monkeys were prepared according to the T-PER TM Tissue Protein Extraction Reagent protocol (Pierce, Rockford, IL). Approximately 250 mg of tissue was homogenized in the extraction reagent containing a protease inhibitor cocktail purchased from Sigma (St Louis, MO). Following homogenization, the samples were centrifuged at 10,000 3 g for 5 min at 4 C to pellet cellular debris. The resulting supernatant was filtered through glass wool, analyzed for protein concentration via the BCA protein assay (Pierce, Rockford, IL), and used for subsequent immunoblotting.
Immunoblot analysis of PMP70. SDS-PAGE was performed using a gradient of 4-12% Tris-Bis precast gels under conditions supplied by the manufacturer (Bio-Rad Laboratories, Inc., Hercules, CA), and the separated proteins were electrophoretically transferred to a PVDF membrane (Bio-Rad Laboratories, Hercules) for 30 min at 100 V. The Odyssey protocol for 2-color immunoblotting was used to allow for simultaneous detection of PMP70 and b-actin (used as control for total protein loaded) and is briefly described here. The membrane was blocked for 1 h at room temperature in Odyssey TM blocking buffer (LI-COR Biosciences, Lincoln, NE), then incubated for 3 h in Odyssey blocking solution containing both the rabbit anti-PMP70 antibody (Affinity Bioreagents, Golden, CO) diluted 1:1000 and the mouse anti-b-actin antibody (Abcam, Inc., Cambridge, MA) diluted 1:4000. After washing of the membrane in PBST (4 times for 5-min each), it was incubated for 1 h at room temperature in Odyssey blocking solution containing a 1:1000 dilution of IRDye TM 800-conjugated goat-antirabbit IgG (Rockland, Gilbertsville, PA) and a 1:5000 dilution of Alexa Fluor TM 680-conjugated goat-anti-mouse IgG (Molecular Probes, Eugene, OR). The membrane was then washed with PBST (4 times for 5 min each), rinsed in PBS, and allowed to air dry. Scanning of the membrane was performed using the 700-and 800-nm channels of an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) for the detection of b-actin and PMP70 protein levels, respectively. Quantitation of PMP70 levels for individual samples was determined by normalizing the signal for PMP70 to the signal obtained with b-actin.
Statistical analysis. A Dunnett's Test was used to compare each treatment group to the control group at a significance level of 0.05 (Dunnett, 1955) . Statistically significant differences are noted by asterisks in the figures.
RESULTS

Dose Response in the Liver of Fenofibrate-treated Rats and
Ciprofibrate-treated Monkeys
The mean rat liver, as percent of body weight after 10 days of fenofibrate treatment, was 3.74, 4.60, 5.15, and 6.04 for the control, 10-, 20-, and 200-mg/kg/day groups, respectively. Formalin-fixed liver sections from these animals were labeled by an indirect method with polyclonal anti-PMP70 and 605 nm Quantum Dots TM . The slides were visualized and photographed under 60X magnification using the DAPI, FITC, and TRITC filter sets described above, and the images were overlaid and deconvolved using image analysis software described above. By visual inspection of Figure 1 , it is apparent that animals treated with 200 mg/kg/day fenofibrate show a dramatic increase in staining and that lower-dose animals also appear to show a slight increase in staining when compared to untreated control animals.
FIG. 1.
Five-mm sections of formalin-fixed liver from male Wistar rats treated with (a) 0, (b) 10, (c) 20, and (d) 200 mg/kg/day of fenofibrate for 10 days and stained with rabbit anti-PMP70, biotinylated goat anti-rabbit IgG and streptavidin-coated 605 nm Quantum Dots. Images captured using 60X oil immersion magnification with DAPI, FITC, and TRITC filter sets were overlaid and deconvolved using image analysis software. Red-orange is the Quantum Dots fluorescence, blue is nuclei, and green is autofluorescence.
QUANTUM DOT VISUALIZATION OF PEROXISOMES
The mean monkey liver as percent body weight after 15 days of ciprofibrate treatment was 2.08, 2.04, 2.24, 3.01, and 4.03 for the control, 3-, 30-, 150-, and 400-mg/kg/day groups, respectively. Formalin-fixed livers from these animals were labeled by an indirect method with polyclonal anti-PMP70 and 605nm Quantum Dots. Visually, the livers appear to exhibit a dose response from 0 to 150 mg/kg/day, but the livers from primates treated with 400 mg/kg/day appear to show a lower level of fluorescence than the 150-mg/kg/day dose (Fig. 2) .
The PMP70 antibody used in these experiments was created by raising antibodies in the rabbit against a 16-mer synthetic peptide; the sequence is from the C-terminal portion of PMP70 in the mouse. In a separate experiment, the primary PMP70 antibody was incubated with a saturating concentration of the 16-mer PMP70 immunogen peptide, and this mixture was used as a substitute for the primary antibody during the staining procedure. This sample did not exhibit fluorescence at 605 nm, indicating that the PMP70 antibody is specific for the 70-kDa peroxisomal membrane protein (data not shown).
Image Analysis of Quantum Dot Peroxisome Fluorescence from Livers of Ciprofibrate-treated Primates
The Quantum Dot peroxisome fluorescence information is contained in the red channel of the RGB image, so quantitation was performed only on the red channel. An 8-bit image has FIG. 2. Five-mm sections of formalin-fixed liver from cynomolgus monkey treated with (a) 0, (b) 3, (c) 30, (d) 150, and (e) 400 mg/kg/day ciprofibrate for 15 days and stained with rabbit anti-PMP70, biotinylated goat anti-rabbit IgG and streptavidin-coated 605 nm Quantum Dots: Images captured using 60X oil immersion magnification with DAPI, FITC, and TRITC filter sets were overlaid and deconvolved using image analysis software. Red-orange is the Quantum Dots fluorescence, blue is nuclei, and green is autofluorescence.
256 shades in each RGB channel, and we quantified the area of those pixels of a given intensity in the red channel. We counted the area of those pixels from bins 125 to 255 (0 is total black and 255 is total white). The choice of bins is somewhat subjective; however, counting bins from 125-255 selected a reasonable area of the slide corresponding to the peroxisome signal. The percent area of the image that contained pixels of intensity 125-255 was then calculated in Image-Pro Plus using a 3 3 3 pixel selector. Native images were deconvoluted, then processed to determine the area of the image contained by peroxisomes. Deconvolution can be particularly useful in analysis of fluorescent signals, in that it can reduce background haze and sharpen the image (Agard et al., 1989) .
Several animals for each dose group were examined and multiple images per slide were examined; a total of 50 images were quantitated using image analysis. Data from each animal is plotted in Figure 3 ; the intra-animal variability can be assessed in this figure. Data is plotted by dose group in Figure 4 , the doseresponse is easily visualized, and the statistical significance by treatment group is given in this figure. The 150-and 400-mg/kg/ day treatment groups were statistically different from the control and the shape of the dose-response curve is identical using native or deconvoluted images. However, the magnitude of the change compared to control (fold-change) is different when using native or deconvoluted images. For example, the fold-change compared to control for the 150-mg/kg/day dose group is 157 and 53 for the native and deconvoluted images, respectively.
Peroxisome Counts from the Livers of Ciprofibrate-treated Primates Using Electron Microscopy (EM)
The number of peroxisomes for all primate livers was quantitated using electron microscopy (data from Hoivik et al., 2004) . Four animals per dose group were treated for 15 days with 0-, 3-, 30-, 150-, or 400-mg/kg/day ciprofibrate, and five EM grids were counted per animal. All dose groups, except the 3-mg/kg/day group, showed a statistically significant increase in peroxisome counts compared to control (Fig. 5) . In contrast to the results with image analysis of Quantum Dots, the EM counts showed (i) the 30-mg/kg/day dose group to be statistically different from the control group, and (ii) the 400-mg/kg/day dose group had a greater response than did the 150-mg/kg/day group.
Peroxisome Area from the Livers of Ciprofibrate-treated Primates Using Electron Microscopy (EM)
An EM morphometric analysis was performed to determine the peroxisome area per field and the relative peroxisome size. The peroxisomal percent area did not show a dose- response   FIG. 3 . Variability in the peroxisome area in the monkey liver, as determined by image analysis within and between animals for a given dose group: Each point represents an area of determination from an animal: between two and four images were analyzed on a given slide and one slide was used per animal. The horizontal line shows the group mean peroxisome area. This data is from the native (not deconvoluted) images. Note that the y-axes have different scales.
QUANTUM DOT VISUALIZATION OF PEROXISOMES relationship and was essentially unchanged for all dose groups (Fig. 5) . However, the size of the peroxisomes decreased with dose (data not shown) and thus the number of peroxisomes increased with dose, but the percentage area did not. The relative size (% area/count) for the peroxisomes was (i) control, 0.08; (ii) 3 mg/kg ciprofibrate, 0.06; (iii ) 30 mg/kg ciprofibrate, 0.05; (iv) 150 mg/kg ciprofibrate, 0.04; and (v) 400 mg/kg ciprofibrate, 0.03.
Biochemical Analysis of the Enzyme Activity from the Livers of Ciprofibrate-treated Primates
The activity of enzymes known, or thought to be related to peroxisomal function was examined in the livers of ciprofibratetreated primates (data from Hoivik et al., 2004) . The enzyme activity was determined for carnitine acetyltransferase, catalase, enoyl-CoA hydratase, and palmitoyl-CoA oxidase, and the results are given in Figure 6 . No dose group for catalase was different from controls, while the other three enzymes showed a statistically significant increase for the 150-mg/kg/day dose groups. In addition, carnitine acetyltransferase and enoylCoA hydratase both showed statistically significant increases for the 400-mg/kg/day dose groups. Interestingly, the shape of the dose-response curves for both carnitine acetyltransferase and FIG. 5. Electron microscopy (EM) peroxisome counts and percent peroxisome area: Treated groups that are statistically different from the control group are noted with an asterisk*; five images were counted per animal. This figure displays data from 100 EM images. The line connects the means for each treatment group. The mean and standard deviation for peroxisome counts for each group are: (i) control, 37.10 6 11.88; (ii) 3 mg/kg/ day ciprofibrate, 35.22 6 12.30; (iii ) 30 mg/kg/day ciprofibrate, 57.96 6 22.32; (iv) 150 mg/kg/day ciprofibrate, 91.83 6 28.76; and (v) 400 mg/kg/day ciprofibrate, 102.70 6 30.11. The mean and standard deviation for the peroxisome area for each group are: (i) control, 3.17 6 1.32; (ii) 3 mg/kg/day ciprofibrate, 2.11 6 0.69; (iii) 30 mg/kg/day ciprofibrate, 3.09 6 1.18; (iv) 150 mg/kg/day ciprofibrate, 3.85 6 1.49; and (v) 400 mg/kg/day ciprofibrate, 2.90 6 1.17.
FIG. 4.
Peroxisome area as determined by image analysis from all monkey livers on a single plot; *treated groups that are statistically different from the control group: Fifty images were quantitated. Data from native (not deconvoluted) images and deconvoluted images are plotted on separate graphs. The line connects the means for each treatment group. The mean and standard deviation of the peroxisome area for each group of native (not deconvoluted) images are (i) control, 0.001037 6 0.001183; (ii) 3 mg/kg/day ciprofibrate, 0.004494 6 0.005339; (iii ) 30 mg/kg/day ciprofibrate, 0.027859 6 0.024520; (iv) 150 mg/kg/day ciprofibrate, 0.163328 6 0.097919; and (v) 400 mg/kg/day ciprofibrate, 0.055752 6 0.036898. The mean and standard deviation for the peroxisome area for each group of deconvoluted images are: (i) control, 0 mg, 0.000308 6 0.000424; (ii) 3 mg/kg/day, 0.000754 6 0.000879; (iii) 30 mg/kg/day, 0.002112 6 0. 001210; (iv) 150 mg/kg/day, 0. 016443 6 0. 008483; and (v) 400-mg/kg/day ciprofibrate, 0.006902 6 0. 004084. palmitoyl-CoA oxidase mirror the shape of the dose response seen with image analysis using Quantum Dots.
Immunofluorescent labeling of Peroxisomes in Human Liver Sections
Sections of formalin-fixed untreated human liver prepared on slides were purchased and labeled with anti-PMP70 and 605-nm Quantum Dots as described above (Fig. 7) . The purpose of this experiment was to determine the range of species crossreactivity of the polyclonal rabbit anti-PMP70. Analysis of the slides with fluorescence microscopy, using a long pass FITC filter set, demonstrated that the rabbit anti-PMP70 does cross-react with human PMP70. The human liver section exhibits a similar staining pattern to those seen in the rat and primate liver sections.
Immunoblot Analysis of PMP70
The relative abundance of PMP70 in the liver of ciprofibratetreated primates was assessed by immunoblotting; results are FIG. 6 . Biochemical analysis of enzymatic activity of carnitine acetyltransferase, catalase, enoyl-CoA hydratase, and palmitoyl-CoA oxidase in the primate liver: The enzymatic activity in the liver of each animal was determined; 20 animals are represented on each plot. Treated groups that are statistically different from the control group are noted with an asterisk (*). Units are in mmol/mg protein/min for catalase and enoyl-CoA hydratase, and in nmol/mg protein/min for carnitine acetyltransferase and palmitoyl-CoA oxidase. The line connects the means for each treatment group.
FIG. 7.
Five-mm section of untreated, formalin-fixed normal human liver stained with rabbit anti-PMP70, biotinylated goat-anti-rabbit IgG, and streptavidin-coated 605 nm Quantum Dots: The image was viewed under 100X oil-immersion magnification with a long pass FITC filter set.
QUANTUM DOT VISUALIZATION OF PEROXISOMES
shown in Figures 8 and 9 . Total protein was isolated from the liver, and PMP70 was detected in all samples. Ciprofibrate at dose levels of 30, 150, and 400 mg/kg/day caused a statistically significant increase in PMP70 protein content compared to control; animals that received 3 mg/kg/day were not analyzed. Mean normalized PMP70 values for animals treated with 30, 150, or 400 mg/kg/day of ciprofibrate were approximately 8-, 17-, and 10-fold higher, respectively, than the normalized control mean (Fig. 9) . Therefore, results from the immunoblot analysis corroborate the results observed with the Quantum Dot method, which showed that the highest level of PMP70 was in the 150 mg/kg/day group.
DISCUSSION
Rodents respond strongly to treatment with PPARa agonists and show a large increase in liver weight and the number of peroxisomes in the liver; rodents also develop hepatocellular carcinoma upon extended treatment (Corton et al., 2000) . Primates, including humans, are considered to be relatively refractory to PPARa agonist-induced peroxisome proliferation and presumably hepatocarcinogenesis (Eacho et al., 1986; Klaunig et al., 2003) . Therefore, we first attempted to detect peroxisome proliferation in the rodent and then examined the primate response. Two PPARa agonists approved for human use, fenofibrate and ciprofibrate, were examined in the rat and monkey. We developed a novel method for peroxisome visualization, which uses an antibody to a peroxisomal membrane protein, PMP70, coupled with detection using Quantum Dots TM , a new fluorophore with desirable optical properties.
In the present study, the 10-mg/kg/day and 200-mg/kg/day doses of fenofibrate in the rat represent 0.3 and 6.0 times the maximum recommended human dose on the basis of mg/meter 2 of surface area; 200 mg/kg/day produced liver carcinoma in the rat and mouse after long-term administration (PDR, 2004) . Pharmacokinetic sampling to determine the AUC and C max was not performed in the rat. The dose levels of ciprofibrate in the monkey in the present study were 3, 30, 150, and 400 mg/kg/day, which represent approximately 0.1, 0.9, 5.3, and 9.4 times the human AUC after a single 100-mg dose (Ferry et al., 1989; Hoivik et al., 2004; Miller and Spence, 1998) .
Somewhat surprisingly, the monkey livers showed a large increase in relative weight, increasing nearly 100% at the highest dose of ciprofibrate used, 400 mg/kg/day. The rat liver relative weight showed a substantial increase at all dose levels, increasing 62% at the highest dose of fenofibrate, 200 mg/kg/day.
We used the QDot/PMP70 method to initially visualize peroxisomes in the rat liver from fenofibrate-treated animals; standard formalin-fixed slides that were about four years old were used. After visualizing a clear dose response in the rat liver, we then developed a method for quantitation based on image analysis and examined the response in the liver of ciprofibrate-treated primates. The data demonstrate that the rabbit anti-PMP70 used in this paper is specific to the PMP70 peptide, and cross-reacts with rat, primate, and human PMP70. This method is efficient and reproducible and requires minimal sample manipulation, unlike more commonly used methods for peroxisome detection, such as electron microscopy.
We also compared the results using the Qdot/PMP70 method with peroxisome count and peroxisome area, as determined by electron microscopy. The fold increase compared to control was much higher for the Qdot/PMP70 method than for the EM peroxisome counts. However, the fold increase in the FIG. 8 . Immunoblot analysis of PMP70: Each lane was loaded with 100 mg of protein isolated from monkeys given 0, 30, 150, or 400 mg/kg/day of ciprofibrate. Four animals per treatment group were examined. Lanes 1-4 represent control animals, lanes 5-8 represent those given 30 mg/kg/day, lanes 9-12 show animals given 150 mg/kg/day, and lanes 13-16 show animals treated with 400 mg/kg/day. Molecular weight standards were loaded on each side of the gel, and the arrows indicate molecular weight markers at 75, 50, and 37 kDa. A major band at approximately 70-kDa was detected in the 800 channel (green) in all samples, which is the expected molecular weight of PMP70. In addition, a major band in all samples at approximately 42 kDa was detected in the 700 channel (red), the expected molecular weight of b-actin, which was used as an internal standard for the amount of protein loaded per lane. image analysis methods is strongly dependent on the methodology used. By EM, the 150-mg/kg/day dose group showed a 2.5-fold increase in counts, while image analysis of the native and deconvoluted images using the Qdot/PMP70 method yielded 163-fold and 44-fold increases in area, respectively.
The most striking difference between the Qdot/PMP70 method and EM counting of peroxisome number is the difference in the shape of the dose-response curve (Figs. 4 and 5) . The EM peroxisome counts generally increased with ciprofibrate dose level, while the Qdot/PMP70 method shows a decrease in PMP70 in the 400-mg/kg/day ciprofibrate group compared to the 150-mg/kg/day treatment group.
The Qdot method has the ability to detect PMP70 protein before the protein is incorporated into functional peroxisomes, while EM counts only fully formed peroxisomes that fulfill certain morphological parameters. Typical liver peroxisomes are between 0.3 and 0.9 mm in size and occupy about 2% of the cell volume, and untreated hepatocytes contain 400-600 peroxisomes (Masters and Crane, 1995) . Furthermore, microperoxisomes are common in mammalian cells, and they are considerably smaller and lack a nucleoid core (Novikoff et al., 1973) . Detection of PMP70 in microperoxisomes, but not in functional peroxisomes, could cause different dose-response curves between the EM counts and the Qdot/PMP70 method. It is our assumption that the PMP70 mass is constant in relationship to the total peroxisome mass.
Using EM, it is also possible to examine the area of the cell occupied by peroxisomes; this is shown in Figure 5 . There was no statistically significant increase at any dose level in percent area by EM. The peroxisomes were smaller in the treated animals when examined by EM; this is why the EM peroxisome count increased while the EM peroxisome percent-area remained relatively constant.
We also determined the liver enzyme activity for carnitine acetyltransferase, catalase, enoyl-CoA hydratase, and palmitoylCoA oxidase from the ciprofibrate-treated primates. These enzymes are often used to give an indication of b-oxidation. However, both the mitochondria and peroxisomes have carnitine acetyltransferase and enoyl-CoA hydratase, so to view these enzymes as solely peroxisomal is an oversimplification (Hiltunen and Qin 2000; Zammit 2000) . Catalase, while often regarded as the single enzyme most closely synonymous with the peroxisome, often shows a very weak response to peroxisome proliferators compared to enzymes in the b-oxidation chain (Masters and Crane, 1995) . Palmitoyl-CoA oxidase is the enzyme that most closely reflects the peroxisomal b-oxidation chain potential (Hawkins et al., 1987) .
The activity of both carnitine acetyltransferase and palmitoylCoA oxidase show a dose-response similar to the Qdot/PMP70 method, in that the 400-mg/kg/day dose group shows a sharp decrease compared to the 150-mg/kg/day dose group. PMP70 is an ATP-binding half-transporter that imports very-long-chain fatty acids for peroxisomal b-oxidation (Imanaka et al., 1999; Kemp et al., 1998; Tanaka et al., 2002) . Given the physiological role of PMP70, it is possible that expression of this protein is coordinately regulated with other components of the peroxisomal b-oxidation pathway, such as carnitine acetyltransferase and palmitoyl-CoA oxidase. It is possible that the Qdot/PMP70 method is a more a reflection of the b-oxidation potential of the peroxisome in the liver than the peroxisomal number.
As a validation of the Qdot/PMP70 method, we examined the levels of primate liver PMP70 protein by immunoblotting. The immunoblot results are similar to results obtained with the Qdot/ PMP70 method, in that the level of PMP70 is greatest for the 150-mg/kg/day group.
The use of Quantum Dots provides the ability to avoid several of the problems commonly encountered with immunofluorescent labeling. The broad-excitation peak and large Stokes shift of the fluorophore allowed us to use a short-excitation wavelength that caused the auto-fluorescent components of the hepatocytes such as flavins to emit fluorescence in the green range, while still exciting the Quantum Dots to emit at 605 nm. Additionally, the photostability of the Quantum Dots provided us with ample time to view the microscopic fields without photo-bleaching the sample. The labeled slides remained fluorescent for weeks after staining, even after being exposed to ambient light during that period.
One of the benefits of our method is that a single common protocol, using the same reagents and conditions, can be used to label peroxisomes from several different species. The properties of the Quantum Dots coupled with the specificity of the PMP70 antibody make this technique sensitive, reliable, and extremely robust.
